Minimal Residual Disease Global Market Report 2025

The minimal residual disease market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historic period can be attributed to the increasing number of cancer patients, growing research and development spending, rising healthcare affordability, the rising prevalence of blood cancer, and increasing awareness among people.

The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.22 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to the rising number of cancer patients, an increase in government awareness programs, improved healthcare affordability, growing disposable income in emerging economies, and initiatives by government bodies to raise cancer awareness. Key trends expected during this period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, the adoption of personalized MRD monitoring, developments in liquid biopsy technologies, and the emergence of minimal residual disease-directed therapies.

The growing prevalence of cancer is anticipated to drive the expansion of the minimal residual disease (MRD) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. Several factors contribute to the increasing prevalence of cancer, including an aging population, greater exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. The rising number of cancer cases has led to a growing demand for precise MRD testing to detect residual cancer cells, enabling early intervention and personalized treatment. This, in turn, enhances relapse prediction and improves patient outcomes. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported that nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022. Projections for 2040 estimate 29.9 million new cases and 15.3 million cancer-related deaths. As a result, the increasing cancer prevalence is fueling the growth of the MRD market.

Leading companies in the MRD market are prioritizing the development of advanced in vitro diagnostic (IVD) test services to offer personalized therapy options and improve patient outcomes. IVD test services are laboratory-based diagnostic methods designed to detect residual cancer cells following treatment, aiding in relapse prediction and therapy optimization. For instance, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, introduced the clonoSEQ Assay for detecting MRD in patients with diffuse large B-cell lymphoma (DLBCL). This test analyzes circulating tumor DNA (ctDNA) in blood samples, providing a highly sensitive, non-invasive method for monitoring cancer progression and identifying early signs of relapse. By offering clinicians a more precise assessment of a patient’s disease burden, the assay helps guide tailored treatment plans. Notably, it is the first MRD test for DLBCL to receive Medicare coverage, ensuring broad accessibility across all treatment regimens and time points.

In February 2024, Veracyte, Inc., a US-based cancer diagnostics company, acquired C2i Genomics, Inc. for $70 million. This acquisition incorporates C2i Genomics' whole-genome MRD expertise into Veracyte's diagnostic platform, enhancing its ability to support patients at various stages of cancer care. C2i Genomics, Inc. is a US-based cancer intelligence company specializing in minimal residual disease (MRD) testing.

Major players in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in minimal residual disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the minimal residual disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment, even when the patient is in clinical remission. Monitoring MRD helps in the early detection of relapse, evaluation of treatment effectiveness, and prediction of recurrence risk. This highly sensitive detection method enables personalized therapies, improving patient outcomes and reducing the chances of relapse.

The primary detection targets for MRD include lymphoma, leukemia, solid tumors, and others. Lymphoma is a type of cancer that originates in the lymphatic system and primarily affects white blood cells called lymphocytes. Various test techniques used for MRD detection include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. These tests are utilized by multiple end-users, including hospitals, diagnostic laboratories, research institutions, and industries such as banking, financial services, and insurance (BFSI), as well as retail and e-commerce.

The minimal residual disease market research report is one of a series of new reports that provides minimal residual disease market statistics, including the minimal residual disease industry global market size, regional shares, competitors with the minimal residual disease market share, detailed minimal residual disease market segments, market trends, and opportunities, and any further data you may need to thrive in the minimal residual disease industry. This minimal residual disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The minimal residual disease market consists of revenues earned by entities by providing services such as cancer monitoring, relapse prediction, personalized treatment plans, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimal residual disease market also includes sales of clonality testing kits, MRD detection reagents, and MRD detection panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.